Johannes Gleiltz

Title: Innovations in Thromboembolic Disorder Treatment: The Contributions of Johannes Gleiltz

Introduction: Johannes Gleiltz, an accomplished inventor based in Darmstadt, Germany, has made significant strides in the field of pharmaceutical chemistry. With a focus on addressing thromboembolic disorders, his innovative work has potential implications in both human and veterinary medicine.

Latest Patents: Johannes Gleiltz holds a patent for Aza-amino acid derivatives, specifically factor Xa inhibitors (patent number details not provided). This invention revolves around semicarbazides characterized by the general formula I. The compounds derived from this formula are designed for use as pharmaceutical active agents. Their applications are particularly relevant in the control and prevention of various thromboembolic disorders, including thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, and intermittent claudication.

Career Highlights: Currently, Johannes Gleiltz is affiliated with Merck Patent GmbH, where he leverages his expertise to contribute significantly to the pharmaceutical field. His work has positioned him as a noteworthy inventor, particularly in the development of novel treatments that address critical health issues.

Collaborations: Throughout his career, Gleiltz has collaborated with notable colleagues, including Werner Mederski and Horst Juraszyk. These collaborative efforts have undoubtedly enriched his research and contributed to the success of his inventions.

Conclusion: Johannes Gleiltz is a pivotal figure in the realm of pharmaceutical innovations. His patent for Aza-amino acid derivatives exemplifies the impactful work being done to tackle serious health concerns related to thromboembolic disorders. As he continues to advance the field through collaborations and innovative thinking, the contributions of inventors like Gleiltz remain crucial for future medical advancements.